Contact Us
Drug Search Results
More Filters [+]

Rizatriptan

Alternative Names: rizatriptan, maxalt
Latest Update: 2024-12-17
Latest Update Note: News Article

Product Description

Rizatriptan is a novel 5-HT1B/1D agonist which is rapidly absorbed after oral administration.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9595867/)

Mechanisms of Action: 5-HT1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Denmark | Egypt | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rizatriptan

Countries in Clinic: Brazil

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Migraine Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EF167

P3

Recruiting

Migraine Disorders

2025-01-30

Recent News Events

Date

Type

Title

12/17/2024

News Article

 Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

12/03/2024

News Article

 Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

11/14/2024

News Article

 Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

09/04/2024

News Article

 Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions